Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 1964-1979

  Huang, Ruili ^a   Wallqvist, Anders ^b   Covell, David G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HEALTH CARE ORGANIZATION; IN VITRO STUDY; IN VIVO STUDY; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; MODELS, STATISTICAL; NATIONAL INSTITUTES OF HEALTH (U.S.); QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; UNITED STATES;

EID: 33645409007     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051029m     Document Type: Article

References (42)

1. Hayflick, L. Recent advances in the cell biology of aging. Mech. Ageing Dev. 1980, 14, 59-79.
2. Baguley, B. C.; Marshall, E. S. In vitro modelling of human tumour behaviour in drug discovery programmes. Eur. J. Cancer 2004, 40, 794-801.
3. Boyd, M. R. The NCI human tumor cell line (60-Cell) screen: Concept, implementation, and applications. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2nd ed.; Humana Press: Totowa, NJ, 2004; pp 41-61.
4. Suggitt, M.; Bibby, M. C. 50 years of preclinical anticancer drug screening: Empirical to target-driven approaches. Clin. Cancer Res. 2005, 11, 971-981.
5. Gonzalez-Nicolini, V.; Fussenegger, M. In vitro assays for anticancer drug discovery - A novel approach based on engineered mammalian cell lines. Anticancer Drugs 2005, 16, 223-228.
6. Tanaka, M.; Bateman, R.; Rauh, D.; Vaisberg, E.; Ramachandani, S.; et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005, 3, e128.
7. Vande Woude, G. F.; Kelloff, G. J.; Ruddon, R. W.; Koo, H. M.; Sigman, C. C.; et al. Reanalysis of cancer drugs: Old drugs, new tricks. Clin. Cancer Res. 2004, 10, 3897-3907.
8. Novotny, L.; Szekeres, T. Recent developments in cancer chemotherapy oriented towards new targets. Expert Opin. Ther. Targets 2005, 9, 343-357.
9. Shoemaker, R. H.; Monks, A.; Alley, M. C.; Scudiero, D. A.; Fine, D. L.; et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog. Clin. Biol. Res. 1988, 276, 265-286.
10. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
11. Voigt, J. H.; Bienfait, B.; Wang, S.; Nieklaus, M. C. Comparison of the NCI open database with seven large chemical structural databases. J. Chem. Inf. Comput. Sci. 2001, 41, 702-712.
12. Wallqvist, A.; Huang, R.; Thanki, N.; Covell, D. G. Evaluating Chemical Structure Similarity as an Indicator of Cellular Growth Inhibition. J. Client. Inf. Model. 2006, 46, 430-437.
13. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
14. Boyd, M. R.; Paull, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
15. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., Jr.; et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275, 343-349.
16. Shi, L. M.; Fan, Y.; Lee, J. K.; Waltham, M.; Andrews, D. T.; et al. Mining and visualizing large anticancer drug discovery databases. J. Chem. Inf. Comput. Sci. 2000, 40, 367-379.
17. Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Mining the National Cancer Institute's tumor-screening database: Identification of compounds with similar cellular activities. J. Med. Chem. 2002, 45, 818-840.
18. Covell, D. G.; Wallqvist, A.; Huang, R.; Thanki, N.; Rabow, A. A.; et al. Linking tumor cell cytotoxicity to mechanism of drug action: An integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 2005, 59, 403-433.
19. Huang, R.; Wallqvist, A.; Covell, D. G. Anticancer metal compounds in NCI's tumor-screening database: Putative mode of action. Biochem. Pharmacol. 2005, 69, 1009-1039.
20. Voskoglou-Nomikos, T.; Pater, J. L.; Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 2003, 9, 4227-4239.
21. Hollingshead, M. G.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci. 1995, 57, 131-141.
22. Decker, S.; Hollingshead, M.; Bonomi, C. A.; Carter, J. P.; Sausville, E. A. The hollow fibre model in cancer drug screening: The NCI experience. Eur. J. Cancer 2004, 40, 821-826.
23. Hall, L. A.; Krauthauser, C. M.; Wexler, R. S.; Hollingshead, M. G.; Slee, A. M.; et al. The hollow fiber assay: Continued characterization with novel approaches. Anticancer Res. 2000, 20, 903-911.
24. Johnson, J. I.; Decker, S.; Zaharevitz, D.; Rubinstein, L. V.; Venditti, J. M.; et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 2001, 84, 1424-1431.
25. Kohonen, T. Self-Organizing Maps; Springer-Verlag: Berlin, 1995.
26. Kohonen, T. The self-organizing map. Neurocomputing 1998, 21, 1-6.
27. Fan, Y.; Shi, L. M.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Quantitative structure-antitumor activity relationships of camptothecin analogues: Cluster analysis and genetic algorithm-based studies. J. Med. Chem. 2001, 44, 3254-3263.
28. Shi, L. M.; Fan, Y.; Myers, T. G.; O'Connor, P. M.; Paull, K. D.; et al. Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues. J. Chem. Inf. Comput. Sci. 1998, 38, 189-199.
29. Ren, S. S.; Lien, E. J. Anticancer agents: Tumor cell growth inhibitory activity and binary QSAR analysis. Curr. Pharm. Des. 2004, 10, 1399-1415.
30. Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR fundamentals and applications in chemistry and biology, volume 1. Hydrophobic, electronic and steric constants, volume 2 [Erratum for J. Am. Chem. Soc. 1995, 117, 9782]. J. Am. Chem. Soc. 1996, 118, 10678.
31. Hansch, C.; Hoekman, D.; Leo, A.; Weininger, D.; Selassie, C. D. Chem-bioinformatics: Comparative QSAR at the interface between chemistry and biology. Chem. Rev. 2002, 102, 783-812.
32. Hansch, C.; Leo, A.; Mekapati, S. B.; Kurup, A. QSAR and ADME. Bioorg. Med. Chem. 2004, 12, 3391-3400.
33. Blower, P. E.; Cross, K. P.; Myatt, G. J.; Yang, C. Building predictive models from high-throughput screening data. Abstracts of Papers. 228th ACS National Meeting, Philadelphia, PA, United States. August 22-26, 2004; American Chemical Society: Washington. DC, 2004; CINF-090.
34. Yang, C.; Cross, K.; Myatt, G. J.; Blower, P. E.; Rathman, J. F. Building predictive models for protein tyrosine phosphatase 1B inhibitors based on discriminating structural features by reassembling medicinal chemistry building blocks. J. Med. Chem. 2004, 47, 5984-5994.
35. Dasmahapatra, G.; Rahmani, M.; Dent, P.; Grant, S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006, 107, 232-240.
36. Hose, C.; Kaur, G.; Sausville, E. A.; Monks, A. Transcriptional profiling identifies altered intracellular labile iron homeostasis as a contributing factor to the toxicity of adaphostin: Decreased vascular endothelial growth factor secretion is independent of hypoxia-inducible factor-1 regulation. Clin. Cancer Res. 2005, 11, 6370-6381.
37. Yu, C.; Rahmani, M.; Almenara, J.; Sausville, E. A.; Dent, P.; et al. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process. Oncogene 2004, 23, 1364-1376.
38. Tormo, J. R.; Gallardo, T.; Peris, E.; Bermejo, A.; Cabedo, N.; et al. Inhibitory effects on mitochondrial complex I of semisynthetic monotetrahydrofuran acetogenin derivatives. Bioorg. Mud. Chem. Lett. 2003, 13, 4101-4105.
39. Tormo, J. R.; Royo, I.; Gallardo, T.; Zafra-Polo, M. C.; Hernandez, P.; et al. In vitro antitumor structure-activity relationships of threo/trans/threo mono-tetrahydrofuranic acetogenins: Correlations with their inhibition of mitochondrial complex I. Oncol. Res. 2003, 14, 147-154.
40. Selzer, P.; Roth, H. J.; Ertl, P.; Schuffenhauer, A. Complex molecules: Do they add value? Curr. Opin. Chem. Biol. 2005, 9, 310-316.
41. Hodes, L. Selection of descriptors according to discrimination and redundancy. Application to chemical structure searching. J. Chem. Inf. Comput. Sci. 1976, 16, 88-93.
42. Hall, D. G.; Manku, S.; Wang, F. Solution- and solid-phase strategies for the design, synthesis, and screening of libraries based on natural product templates: A comprehensive survey. J. Comb. Chem. 2001, 3, 125-150.